Hannah Valantine sold $1.7M of BridgeBio Pharma (BBIO)

Executed Nov 12 2025, disclosed Nov 14 2025, 2 days later.

Value, as filed

$1.7M

25,484 sh × $66.07

Executed

Nov 12 2025

the trade date, as filed

Disclosed

Nov 14 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Hannah Valantine Director profile →

Hannah Valantine (Director) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in BridgeBio Pharma, Inc. (BBIO). The largest single filing was $1.7M of BBIO (25,484 sh across 2 lots, as filed), executed Feb 27.

The name

BBIO

BridgeBio Pharma, Inc. BBIO · Healthcare · 71 filings in 24 months ticker →

Healthcare · BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Hannah Valantine in BBIO

BBIOSALE BridgeBio Pharma, Inc. $342K
5,004 sh across 2 lots
Exec Jun 22
Filed Jun 24 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $624K
8,671 sh × $72.00
Exec Mar 10
Filed Mar 12 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $1.7M
25,484 sh across 2 lots
Exec Feb 27
Filed Mar 3 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $172K
4,292 sh × $40.00
Exec Jun 10 2025
Filed Jun 11 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $419K
12,875 sh × $32.58
Exec Mar 6 2025
Filed Mar 10 2025 · 5:30 PM ET